Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities

Colorectal cancer (CRC) is the third most diagnosed type of cancer and the third most common cause of cancer-related death worldwide [1]. Overall survival (OS) after 5 years from diagnosis of CRC is around 60% [2]. Median OS for patients with metastatic CRC (mCRC) is up to 30 months, progressively increasing alongside the last two decades [2 –6]. However, despite recent discoveries in precision oncology and immunotherapy of tumors, treatment developments in CRC have been incremental rather than transformative.

Source: Cancer Treatment Reviews - October 8, 2020 Category: Cancer & Oncology Authors: Gianluca Mauri, Viviana Gori, Erica Bonazzina, Alessio Amatu, Federica Tosi, Katia Bencardino, Lorenzo Ruggieri, Giorgio Patelli, Sabrina Arena, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi Tags: Systematic or Meta-analysis Studies Source Type: research